Condensed Consolidated Statements of Cash Flows $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023 USD ($)		Sep. 30, 2023 USD ($)		Sep. 30, 2022 USD ($)
Cash Provided by (Used in) Operating Activities
Net earnings	$ 2,166		$ 6,070		$ 3,074
Adjustments to reconcile net earnings to operating cash flows:
Depreciation and amortization			194		163
Deferred income tax provision (benefit)			(575)		(550)
Unrecognized tax benefit			1,173	[1]	21
(Income) losses from investments in equity securities	(58)		(105)		3,707
Dividends from ABI			163		104
Loss on Cronos-related financial instruments	0		0		14
Cash effects of changes
Receivables			19	[2]	(5)
Inventories			26	[2]	88
Accounts payable			(47)	[2]	(27)
Income taxes			(210)	[2]	49
Accrued liabilities and other current assets			(210)	[2]	(382)
Accrued settlement charges			(537)	[2]	(618)
Pension plan contributions			(14)		(11)
Pension and postretirement, net			(97)		(110)
Other, net			210		120
Net cash provided by (used in) operating activities			6,060		5,637
Cash Provided by (Used in) Investing Activities
Capital expenditures			(143)		(147)
Proceeds from the sale of IQOS System commercialization rights			1,700		0
Acquisition of NJOY, net of cash acquired			(2,751)		0
Other, net			(23)		(68)
Net cash provided by (used in) investing activities			(1,217)		(215)
Cash Provided by (Used in) Financing Activities
Proceeds from short-term borrowings			2,000		0
Repayment of short-term borrowings			(2,000)		0
Long-term debt repaid			(1,566)		(1,105)
Repurchases of common stock			(732)		(1,451)
Dividends paid on common stock			(5,040)		(4,908)
Other, net			(15)		(12)
Net cash provided by (used in) financing activities			(7,353)		(7,476)
Cash, cash equivalents and restricted cash:
Increase (decrease)			(2,510)		(2,054)
Balance at beginning of period			4,091		4,594
Balance at end of period	1,581		1,581		2,540
Cash and cash equivalents	1,537		1,537
Restricted cash included in other current assets	10	[3]	10	[3]
Restricted cash included in other assets	34	[3]	34	[3]
Cash, cash equivalents and restricted cash	$ 1,581		$ 1,581		$ 2,540

[1] 2023 relates to unrecognized tax benefit from the ordinary loss for cash tax purposes with respect to a portion of our tax basis associated with our former investment in JUUL. For further discussion, see Note 12. Income Taxes.

[2] 2023 amounts are net of the effects from the NJOY Transaction. For further details, see Note 2. Acquisition of NJOY.

[3] Restricted cash consisted primarily of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 13. Contingencies.